Oppenheimer Sticks to Its Buy Rating for Acrivon Therapeutics, Inc. (ACRV)

Business Insider

15-05-2025

Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Acrivon Therapeutics, Inc. (ACRV – Research Report) yesterday and set a price target of $9.00. The company's shares closed yesterday at $1.14.
Confident Investing Starts Here:
Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Biegler is an analyst with an average return of -16.2% and a 27.06% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Regeneron, and IDEAYA Biosciences.
Acrivon Therapeutics, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $11.43.
ACRV market cap is currently $37.63M and has a P/E ratio of -0.46.
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ACRV in relation to earlier this year.